A recent analysis of data from the Canadian Cancer Trials Group (CCTG) CO.17 randomized controlled trial found cetuximab treatment was associated with overall survival (OS) benefit in patients with metastatic wild‐type KRAS colorectal cancer who had the FCGR2A H/H genotype but not those with the R/‐ genotype. The gene discussed is KRAS; the disease is colorectal cancer.